{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:44:28Z","timestamp":1793054668349,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>GLP-1 agonists have been a welcome addition to the armamentarium in the treatment of diabetes and obesity. While this class of medications is generally considered safe and effective, potentially severe neurological complications may be associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use. We present a 37-year-old woman who was prescribed semaglutide for diabetes and weight loss who subsequently experienced significant weight reduction and rapid glycemic control over three months. Thereafter, she developed progressive right leg numbness and weakness, followed by similar symptoms in the left leg, and blurred vision. Initially diagnosed with B12 deficiency, her symptoms worsened despite supplementation, leading to acute encephalopathy and transfer to a tertiary center. Neurological examination revealed disorientation, ocular abnormalities, weakness, sensory deficits, and preserved ankle jerks. Diagnostic workup was notable for thiamine deficiency, NCS\/EMG showing a severe, axonal polyneuropathy, and nerve biopsy redemonstrating severe axonal neuropathy. After extensive diagnostic workup, the most likely etiology of her clinical presentation was favored to be non-alcoholic Wernicke\u2019s encephalopathy (NAWE) and treatment-induced neuropathy of diabetes (TIND). This case suggests that vulnerable individuals may experience significant adverse neurological complications from the metabolic effects of GLP-1 agonist use. As a class effect, the benefits of these medications outweigh the risks, but their use warrants consideration of their potential sequelae.<\/jats:p>","DOI":"10.1186\/s12883-025-04540-7","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T08:24:34Z","timestamp":1764145474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Ali","family":"Zahir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyvonne","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Samghabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja C.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara C.","family":"LaHue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"1","key":"4540_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/nyas.14536","volume":"1498","author":"TJ Smith","year":"2021","unstructured":"Smith TJ, Johnson CR, Koshy R, Hess SY, Qureshi UA, Mynak ML, et al. Thiamine deficiency disorders: a clinical perspective. Ann N Y Acad Sci. 2021;1498(1):9\u201328.","journal-title":"Ann N Y Acad Sci"},{"key":"4540_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130.","journal-title":"Mol Metab"},{"issue":"7","key":"4540_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s10571-008-9297-7","volume":"28","author":"A B\u00e2","year":"2008","unstructured":"B\u00e2 A. Metabolic and structural role of thiamine in nervous tissues. Cell Mol Neurobiol. 2008;28(7):923\u201331.","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"4540_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0022-510X(82)90145-9","volume":"56","author":"A Torvik","year":"1982","unstructured":"Torvik A, Lindboe CF, Rogde S. Brain lesions in alcoholics: A neuropathological study with clinical correlations. J Neurol Sci. 1982;56(2):233\u201348.","journal-title":"J Neurol Sci"},{"key":"4540_CR5","doi-asserted-by":"publisher","first-page":"102668","DOI":"10.1016\/j.autneu.2020.102668","volume":"226","author":"CH Gibbons","year":"2020","unstructured":"Gibbons CH. Treatment induced neuropathy of diabetes. Auton Neurosci. 2020;226:102668.","journal-title":"Auton Neurosci"},{"issue":"9","key":"4540_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.nrl.2016.06.007","volume":"33","author":"R Cuenca Hern\u00e1ndez","year":"2018","unstructured":"Cuenca Hern\u00e1ndez R, Segura Galindo A, Mart\u00ednez Acebes E. Insulin neuritis or treatment-induced diabetic neuropathy. Neurologia. 2018;33(9):616\u20138.","journal-title":"Neurologia"},{"issue":"2","key":"4540_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/CND.0000000000000330","volume":"22","author":"T Wannarong","year":"2020","unstructured":"Wannarong T, Katirji B. Painless diabetic lumbosacral radiculoplexus neuropathy: A manifestation of Treatment-Induced neuropathy of diabetes. J Clin Neuromuscul Dis. 2020;22(2):121.","journal-title":"J Clin Neuromuscul Dis"},{"key":"4540_CR8","unstructured":"Dydyk AM, Hameed S. Lumbosacral Plexopathy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Apr 20]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556030\/"},{"issue":"3","key":"4540_CR9","doi-asserted-by":"publisher","first-page":"e213916","DOI":"10.1212\/WNL.0000000000213916","volume":"105","author":"JD Triplett","year":"2025","unstructured":"Triplett JD, Pinto MV, Young NP, Staff NP, Chinmay MS, Horowitz M, Aragon Pinto C, Laughlin RS, Shouman K, Berini SE, Mauermann ML. GLP-1RA\u2013Associated diabetic lumbosacral radiculoplexus and common fibular neuropathies: A Case-Control evaluation. Neurology. 2025;105(3):e213916.","journal-title":"Neurology"},{"key":"4540_CR10","unstructured":"Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2025 Apr 20]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279141\/"},{"issue":"16","key":"4540_CR11","doi-asserted-by":"publisher","first-page":"e2098","DOI":"10.1212\/WNL.0000000000011799","volume":"96","author":"MV Pinto","year":"2021","unstructured":"Pinto MV, Ng PS, Howe BM, Laughlin RS, Thapa P, Dyck PJ, et al. Lumbosacral radiculoplexus neuropathy: neurologic outcomes and survival in a Population-Based study. Neurology. 2021;96(16):e2098\u2013108.","journal-title":"Neurology"},{"issue":"5","key":"4540_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4103\/aian.aian_239_22","volume":"25","author":"A Agarwal","year":"2022","unstructured":"Agarwal A, Srivastava MVP, Vishnu VY. Diabetic amyotrophy (Bruns-Garland Syndrome): A narrative review. Ann Indian Acad Neurol. 2022;25(5):841\u20134.","journal-title":"Ann Indian Acad Neurol"},{"key":"4540_CR13","doi-asserted-by":"crossref","unstructured":"Rashed H, Shouman K, Pinto CA, Pinto MV, Dyck P, Engelstad J, Daley C, Klein C, Dyck PJ. Ischemic Injury and Microvasculitis in Treatment Induced Neuropathy of Diabetes (P9-11.013). In Neurology 2024 Apr 14 (Vol. 102, No. 7_supplement_1, p. 6084).","DOI":"10.1212\/WNL.0000000000206224"},{"key":"4540_CR14","unstructured":"Sheth K, Garza E, Saju A, Nazir N, Agarwal A. Wernicke encephalopathy associated with semaglutide use. Cureus 16(6):e61783."},{"key":"4540_CR15","doi-asserted-by":"publisher","first-page":"1416985","DOI":"10.3389\/fphar.2024.1416985","volume":"15","author":"L He","year":"2024","unstructured":"He L, Li Q, Yang Y, Li J, Luo W, Huang Y, et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Front Pharmacol. 2024;15:1416985.","journal-title":"Front Pharmacol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04540-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04540-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04540-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T20:02:25Z","timestamp":1767470545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-025-04540-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4540"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04540-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was conducted according to the Helsinki Declaration, Belmont Report, International Ethical Guideline for Biomedical Research Involving Human Subjects and Council of International Organizations of Medical Sciences. Written informed consent was obtained from the patient to participate in this case report with anonymised data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for their personal or clinical details along with any identifying images to be published in this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}